دورية أكاديمية
Pooled Population Pharmacokinetic Analysis and Dose Recommendations for Ciprofloxacin in Intensive Care Unit Patients with Obesity.
| العنوان: | Pooled Population Pharmacokinetic Analysis and Dose Recommendations for Ciprofloxacin in Intensive Care Unit Patients with Obesity. |
|---|---|
| المؤلفون: | van Rhee KP; Department of Clinical Pharmacy, Tergooi MC, Hilversum, The Netherlands.; Department of Clinical Pharmacy, St Jansdal Hospital, Harderwijk, The Netherlands.; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden, The Netherlands., Brüggemann RJM; Department of Pharmacy and Radboud Institute of Health Science, Radboud University Medical Center, Nijmegen, The Netherlands.; Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands., Roberts JA; University of Queensland, Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.; Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Australia.; Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.; Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France., Sjövall F; Department of Intensive Care and Perioperative Medicine, Skane University Hospital, Malmö, Sweden.; Mitochondrial Medicine, Lund University, Lund, Sweden., van Hest RM; Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Elbers PWG; Department of Intensive Care Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Abdulla A; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands., van der Linden PD; Department of Clinical Pharmacy, Tergooi MC, Hilversum, The Netherlands., Knibbe CAJ; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden, The Netherlands.; Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands. |
| المصدر: | Journal of clinical pharmacology [J Clin Pharmacol] 2024 May 12. Date of Electronic Publication: 2024 May 12. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2013- : Oxford : Wiley Original Publication: Stamford, Conn., Hall Associates. |
| مستخلص: | Recent studies have explored the influence of obesity and critical illness on ciprofloxacin pharmacokinetics. However, variation across the subpopulation of individuals with obesity admitted to the intensive care unit (ICU) with varying renal function remains unexamined. This study aims to characterize ciprofloxacin pharmacokinetics in ICU patients with obesity and provide dose recommendations for this special population. Individual patient data of 34 ICU patients with obesity (BMI >30 kg/m 2 ) from four studies evaluating ciprofloxacin pharmacokinetics in ICU patients were pooled and combined with data from a study involving 10 individuals with obesity undergoing bariatric surgery. All samples were collected after intravenous administration. Non-linear mixed effects modeling and simulation were used to develop a population pharmacokinetic model and describe ciprofloxacin exposure in plasma. Model-based dose evaluations were performed using a pharmacokinetic/pharmacodynamic target of AUC/MIC >125. The data from patients with BMI ranging from 30.2 to 58.1 were best described by a two-compartment model with first-order elimination and a proportional error model. The inclusion of Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) as a covariate on clearance reduced inter-individual variability from 57.3% to 38.5% (P < .001). Neither body weight nor ICU admission significantly influenced clearance or volume of distribution. Renal function is a viable predictor for ciprofloxacin clearance in ICU patients with obesity, while critical illness and body weight do not significantly alter clearance. As such, body weight and critical illness do not need to be accounted for when dosing ciprofloxacin in ICU patients with obesity. Individuals with CKD-EPI >60 mL/min/1.73 m 2 may require higher dosages for the treatment of pathogens with minimal inhibitory concentration ≥0.25 mg/L. (© 2024 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.) |
| References: | EUCAST Ciprofloxacin: Rationale for EUCAST Clinical Breakpoints. Accessed August 9, 2023. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Ciprofloxacin_Rationale_Document_2.0_20210101.pdf. Ciprofloxacin prescribers information. Accessed August 9, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/Label/2016/019537s086lbl.pdf. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37(5):1073‐1081. Roberts JA, Alobaid AS, Wallis SC, Perner A, Lipman J, Sjöval F. Defining optimal dosing of ciprofloxacin in patients with septic shock. J Antimicrob Chemother. 2019;74(6):1662‐1669. Abdulla A, Rogouti O, Hunfeld NGM, et al. Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients. Eur J Clin Pharmacol. 2020;76(7):957‐967. Gieling EM, Wallenburg E, Frenzel T, et al. Higher dosage of ciprofloxacin necessary in critically ill patients: a new dosing algorithm based on renal function and pathogen susceptibility. Clin Pharmacol Ther. 2020;108:770‐774. Guo T, Abdulla A, Koch BCP, et al. Pooled population pharmacokinetic analysis for exploring ciprofloxacin pharmacokinetic variability in intensive care patients. Clin Pharmacokinet. 2022;61(6):869‐879. Guideline for Empirical Antibacterial Therapy of Sepsis in Adults. Accessed August 9, 2023. https://swab.nl/exec/file/download/144. van Rhee KP, Smit C, Wasmann RE, et al. Ciprofloxacin pharmacokinetics after oral and intravenous administration in (morbidly) obese and non‐obese individuals; a prospective clinical study. Clinical pharmacokinetics. 2022;61:1167‐1175. van Zanten ARH, Polderman KH, van Geijlswijk IM, van der Meer GYG, Schouten MA, Girbes ARJ. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care. 2008;23(3):422‐430. Inker LE, Eneanya ND, Coresh J, Chronic Kidney Disease Epidemiology Collaboration, et al. New creatinine‐ and cystatin C‐based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737‐1749. Levey AS. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Annals Intern Med. 2006;145:247‐254. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31‐41. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Archives of Internal Medicine. 1916;17:863‐871. WMA. Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects. WMA; 2013. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. Good Clinical Practice. ICH; 2016. Beal S, Sheiner L, Boeckmann A. NONMEM Users Guide—Part IV. NONMEM Project Group University of California at San Francisco; 2018. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051‐1065. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24(5):643‐647. Alobaid AS, Hites M, Lipman J, Taccone FS, Roberts JA. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review. Int J Antimicrob Agents. 2016;47(4):259‐268. Roggeveen L F, Guo T, Fleuren LM, et al. Right dose, right now: bedside, real‐time, data‐driven, and personalised antibiotic dosing in critically ill patients with sepsis or septical shock ‐ a two‐centre randomised clinical trial. Critical care. 2022;26:265. Rubio TT, Miles MV, Lettieri JT, Kuhn RJ, Echols RM, Church DA. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr Infect Dis J. 1997;16(1):112‐117. |
| فهرسة مساهمة: | Keywords: ICU patients; ciprofloxacin; dosing; obesity; pharmacokinetics |
| تواريخ الأحداث: | Date Created: 20240512 Latest Revision: 20240512 |
| رمز التحديث: | 20240513 |
| DOI: | 10.1002/jcph.2450 |
| PMID: | 38736038 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1552-4604 |
|---|---|
| DOI: | 10.1002/jcph.2450 |